Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[RANKL vaccination].

Takuo Juji1, Sakae Tanaka

  • 1Department of Orthopaedic Surgery, National Hospital Organization Sagamihara Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Treatment for Toe Deformities in Stiff-Person Syndrome: A Case Report.

JBJS case connector·2020
Same author

Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.

Journal of bone and mineral metabolism·2020
Same author

The small compound, TD-198946, protects against intervertebral degeneration by enhancing glycosaminoglycan synthesis in nucleus pulposus cells.

Scientific reports·2020
Same author

Predictive factors of the 30-day mortality after surgery for spinal metastasis: Analysis of a nationwide database.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020
Same author

In vivo length change of ligaments of normal knees during dynamic high flexion.

BMC musculoskeletal disorders·2020
Same author

Surgical margin for phosphaturic mesenchymal tumors in soft tissues: An analysis of the radiological histopathological correlation.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

A novel therapeutic vaccine targeting RANKL offers a promising new strategy for inhibiting bone destruction in conditions like osteoporosis and rheumatoid arthritis. This approach requires smaller protein doses than other treatments and provides a sustained effect through booster vaccinations.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Context:

  • Pathological bone loss, including osteoporosis, rheumatoid arthritis, and bone metastasis, presents a significant clinical challenge.
  • Current therapeutic strategies often involve recombinant proteins like monoclonal antibodies, soluble receptors, or other antagonists.
  • These treatments can be costly and require repeated administration.

Purpose:

  • To introduce a novel therapeutic vaccine approach targeting Receptor Activator of Nuclear Factor kappa-B Ligand (RANKL).
  • To evaluate the potential of RANKL vaccination as a treatment for pathological bone loss conditions.
  • To compare the efficacy and dosage requirements of a vaccine-based therapy against existing protein-based treatments.

Summary:

  • A therapeutic vaccine targeting RANKL is proposed as a method to inhibit bone destruction.

Related Experiment Videos

  • Vaccination requires significantly smaller protein doses compared to alternative therapies such as monoclonal antibodies or soluble receptors.
  • The immune response generated by the vaccine can be maintained through booster administrations, offering a sustained therapeutic effect.

    • Impact:

    • This RANKL vaccination represents a novel therapeutic strategy for a wide range of pathological bone conditions.
    • The approach may offer a more cost-effective and convenient treatment option due to lower dosage requirements.
    • Successful implementation could lead to improved management of debilitating bone diseases and enhanced patient quality of life.